Cellsearch(R) Circulating Tumor Cells, Colon

The Cellsearch(R) Circulating Tumor Cells, Colon test contains 1 test with 1 biomarker.

This test can detect the presence of circulating tumor cells (CTC) in the peripheral blood of patients with metastatic breast cancer, colorectal or prostate cancer in patients. A count of 5 CTC or more in breast and prostate cancers and 3 CTC or more in colon cancer in 7.5 mL of blood is predictive of shorter progression free survival and overall survival. Physicians can draw samples prior to a new line of therapy for baseline prediction. Physicians can also draw samples at the first follow-up visit for evaluating response to therapy. The Veridex CellSearch® System is the only semi-automated system designed to standardize and optimize the measurement of CTC in peripheral blood, this test is also the only FDA approved kit for CTC detection.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: CellsearchR Circulating Tumor Cells Colon

Cellsearch(R) Circulating